PUMA protein coordinates the cell-suicide activities of p53 in the nucleus and cytoplasm

September 08, 2005

(MEMPHIS, TENN.-Sept. 8, 2005) The discovery of how the activities of the protein p53 initiate signals that trigger cell suicide offers critical insights for developing new anti-cancer drugs, according to investigators from St. Jude Children's Research Hospital. A report on this work appears in the September 9 issue of Science.

The new study showed that the protein PUMA frees p53 from the grip of a third protein, Bcl-xL, so p53 can activate the series of signals that triggers programmed cell suicide, or apoptosis. Apoptosis is the mechanism by which abnormal cells are eliminated from the body before they can cause disease, including cancer. For example, if the cell suffers a non-repairable injury to its genetic material, the p53 gene becomes active and produces the p53 protein, which accumulates both in the nucleus and cytoplasm of the damaged cell. The accumulation of p53 in the cytoplasm and nucleus each contribute to apoptosis, but until this finding, scientists did not know these contributions were linked.

The study's finding solves the long-standing puzzle of why p53 activity occurs in both the nucleus and cytoplasm during apoptosis, according to Jerry E. Chipuk, Ph.D., now a post-doctoral fellow in the Department of Immunology at St. Jude Children's Research Hospital. Chipuk is the first author of the Science article. This work was completed, before his appointment at St. Jude, with colleagues at the La Jolla Institute for Allergy and Immunology and the University of Iowa.

The researchers propose the following scenario for the role of PUMA in apoptosis: First, p53 inside the nucleus regulates the expression (activity) of several genes linked to apoptosis, including PUMA. The PUMA protein is then produced in the cytoplasm, where other p53 proteins are bound to Bcl-xL. Finally, PUMA binds to the p53/Bcl-xL pair, causing p53 to break free. After p53 is liberated, it triggers a series of signals on the cell's mitochondria-tiny membrane-bound capsules of enzymes that produce the energy-rich molecules required for cellular activities. The membranes covering mitochondria become punctured, allowing certain molecules to leak out and engage the process of apoptosis.

The binding of PUMA to the p53/Bcl-xL pair creates what Chipuk describes as the "tripartite nexus" (three-part connection) that orchestrates the complex web of signals leading to apoptosis.

"Our scenario consolidates a lot of evidence from our group and other researchers to explain how p53, Bcl-xL, and PUMA work together to trigger apoptosis," said Douglas Green, Ph.D., chair of the Immunology Department at St. Jude and senior author of the paper. Green previously led the Division of Cellular Immunology at the La Jolla Institute of Allergy and Immunology (San Diego, CA). A leader in the field of apoptosis, he will integrate immune system research into the ongoing efforts of St. Jude to improve diagnosis and treatment of childhood catastrophic diseases.

"The concept of the tripartite nexus also gives us insight into how to develop novel drugs to save certain cells," Green said. "For example, if we could block the formation of the nexus in children receiving radiation or chemotherapy for cancer, we might be able to save otherwise healthy cells from the side effects of these treatments. Or, we might be able to encourage the formation of the tripartite nexus in cells that pose a threat to the body."

Green's team studied the interaction of p53, Bcl-xL and PUMA in laboratory models of cells. The researchers combined a p53/Bcl-xL pair with the cytosol (liquid part) of cells that had been exposed to ultraviolet (UV) radiation. UV radiation damages genes and normally would cause the tripartite nexus to assemble in order to trigger apoptosis.

Cytosol from normal cells containing the PUMA gene disrupted the Bcl-xL/p53 complex; but cytosol from cells lacking this gene did not disrupt the complex. This strongly suggested that PUMA is needed to free p53 from Bcl-xL.

In addition, the researchers showed that when an excessive amount of p53 was present, PUMA was no longer required to release p53 from Bcl-xL. This occurred, for example, when there was not enough Bcl-xL to bind all of the p53 that was produced by multiple damaging events to the cell's genetic material. In this scenario, even in the absence of PUMA, enough free p53 was available to cause the membranes of mitochondria to be punctured and apoptosis to occur.

The team also showed that in the absence of the p53 gene, PUMA itself could not trigger the puncturing of mitochondria and subsequent apoptosis.

Other authors of the paper include Lisa Bouchier-Hayes and Donald D. Newmeyer (La Jolla Institute for Allergy and Immunology) and Tomomi Kuwana (La Jolla Institute for Allergy and Immunology; currently at the University of Iowa, Department of Pathology, Iowa City, IA). This work was supported in part by the National Institutes of Health and an Individual National Research Service Award to Jerry E. Chipuk.
-end-
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization. For more information, please visit www.stjude.org.

St. Jude Children's Research Hospital

Related Mitochondria Articles from Brightsurf:

Researchers improve neuronal reprogramming by manipulating mitochondria
Researchers at Helmholtz Zentrum M√ľnchen and Ludwig Maximilians University Munich (LMU) have identified a hurdle towards an efficient conversion: the cell metabolism.

Inside mitochondria and their fascinating genome
EPFL scientists have observed -- for the first time in living cells -- the way mitochondria distribute their transcriptome throughout the cell, and it involves RNA granules that turn out to be highly fluid.

'Cheater mitochondria' may profit from cellular stress coping mechanisms
Cheating mitochondria may take advantage of cellular mechanisms for coping with food scarcity in a simple worm to persist, even though this can reduce the worm's wellbeing.

A ribosome odyssey in mitochondria
The ciliate mitoribosome structure provides new insights into the diversity of translation and its evolution.

Fireflies shed light on the function of mitochondria
By making mice bioluminescent, EPFL scientists have found a way to monitor the activity of mitochondria in living organisms.

First successful delivery of mitochondria to liver cells in animals
This experiment marks the first time researchers have ever successfully introduced mitochondria into specific cells in living animals.

Lack of mitochondria causes severe disease in children
Researchers at Karolinska Institutet in Sweden have discovered that excessive degradation of the power plants of our cells plays an important role in the onset of mitochondrial disease in children.

Unexpected insights into the dynamic structure of mitochondria
As power plants and energy stores, mitochondria are essential components of almost all cells in plants, fungi and animals.

Mitochondria are the 'canary in the coal mine' for cellular stress
Mitochondria, tiny structures present in most cells, are known for their energy-generating machinery.

Master regulator in mitochondria is critical for muscle function and repair
New study identifies how loss of mitochondrial protein MICU1 disrupts calcium balance and causes muscle atrophy and weakness.

Read More: Mitochondria News and Mitochondria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.